Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A2 | P11168 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12017652 | 0.88 | SLC2A2 (0.46) | SLC2A2MAPK1GAAKDM4ERXFP1 | |
| SCHEMBL10038836 | 0.84 | ALDH1A1 (0.39) | MAPK1GAAKDM4EKMT2ARAB9A | |
| SCHEMBL3594242 | 0.79 | SLC2A2 (0.46) | SLC2A2MAPK1GAANPC1RAB9A | |
| SCHEMBL13500447 | 0.76 | MAPK1 (0.50) | MAPK1GAAKDM4ERXFP1KMT2A | |
| SCHEMBL2260441 | 0.76 | KDM4E (0.47) | SLC2A2GAAKDM4ERXFP1KMT2A | |
| SCHEMBL16115202 | 0.74 | SLC2A2 (0.47) | SLC2A2GAAKDM4ERXFP1MAPT | |
| SCHEMBL3594244 | 0.72 | SLC2A2 (0.46) | SLC2A2MAPK1GAAKDM4ENPC1 | |
| SCHEMBL27500927 | 0.72 | GABRA1 (0.72) | SLC2A2KDM4ENPC1RAB9A | |
| SCHEMBL23624072 | 0.70 | SLC2A2 (0.82) | SLC2A2MAPK1GAAKDM4EMAPT | |
| SCHEMBL10299459 | 0.69 | CYP4Z1 (0.57) | MAPK1GAAKDM4EKMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193236-B2 | Indolylmaleimide derivatives processes for their production and pharmaceutical compositions | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-20100041693-A1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041693-A1 | INDOLYLMALEIMIDE DERIVATIVES | IDH3A, IDH2, INMT | SLC2A2 2956/4885MAPK1 3536/4885GAA 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.